Pulmonary Arterial Hypertension

Patients With PAH Can Safely Transition From Bosentan and Sildenafil to Alternative Therapy

April 21st 2021, 1:30pm


While bosentan and sildenafil is a common combination therapy in patients with pulmonary arterial hypertension (PAH), patients may need to transition to alternative therapy because of the potential for drug-drug interactions with this combination.

Educational Support Can Improve Compliance to Oral PAH Therapies

April 18th 2021, 1:15pm


An educational nursing program can positively impact medication compliance in patients receiving oral pulmonary arterial hypertension (PAH) therapies.

PAH Treatment Patterns and Costs Related to Hospitalization

April 15th 2021, 1:45pm


New research presented at AMCP 2021, the annual meeting of the Academy of Managed Care Pharmacy, evaluated treatment patterns and costs related to hospitalization for patients with pulmonary arterial hypertension (PAH).

Better Understanding of Potential Genetic Mutations May Lead to Improved PAH Diagnosis, Treatment

April 13th 2021, 4:25pm


A better understanding of the genetic etiology of pulmonary arterial hypertension and its molecular variants is needed to develop better therapies for the disease, which has no agents available that can reverse or halt it.

Assessing Nutritional Risk Can Predict PAH Prognosis at First Hospitalization

April 6th 2021, 9:28pm


Adjunct nutritional therapies may be a simple way to improve the prognosis for patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension who are hospitalized.

SPHERE Registry Provides Snapshot of Selexipag to Treat PAH in the Real World

April 5th 2021, 6:46pm


Registry of patients with pulmonary arterial hypertension (PAH) treated with selexipag provides insights into real-world dosing regimens and outcomes.

Iron Replacement Has No Impact on Disease Severity, Quality of Life in PAH

April 1st 2021, 8:57pm


Idiopathic pulmonary arterial hypertension (PAH) is associated with iron deficiency, which is in turn associated with worse functional capacity and survival in PAH; however, iron repletion by infusion provided no significant clinical benefit.

Evaluating Efficacy of Initial Combination Therapy on Pulmonary Vascular Resistance

March 27th 2021, 6:00pm


An ongoing multicenter study in Japan will evaluate reductions in pulmonary vascular resistance 8 months after initiating the combination therapy in pulmonary arterial hypertension.

Survey Finds Unmet Needs Despite Good HRQOL for Patients With PAH

March 21st 2021, 8:15pm


Despite patients with pulmonary arterial hypertension reporting good quality of life and low symptom severity, functional limitations persisted, suggesting improvements to the patient experience are needed, according to researchers.

Patients With PAH Have Similar Incidence of COVID-19, but Potentially Worse Outcomes

March 18th 2021, 1:15pm


Patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension had similar incidence of COVID-19, but the impact on clinical operations at the centers that treat these patients was substantial.